BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT), a biotechnology company developing targeted, safe treatments for cancer, this morning announced the appointment of Dr. Rebecca Taub, M.D., and Vaughn C. Embro-Pantalony to its board of directors. Dr. Saeid Babaei, Rahoul Sharan and Martin Schmieg have resigned from BriaCell’s board of directors, effective immediately. Since 2016, Taub has served as chief medical officer; executive vice president, R&D; and director of the board for Madrigal Pharmaceuticals (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics. She acted as privately-held Madrigal Pharmaceuticals Inc.’s chief executive officer and director of the board since its inception, through to its merger with Synta Pharmaceuticals Corp. Embro-Pantalony is chairman of the board of Soricimed Biopharma Inc., a private clinical-stage biopharma company developing targeted cancer therapies. He also serves as a director for Microbix Biosystems Inc. (OTC: MBXBF), a leading manufacturer of viral and bacterial antigens and reagents for the global diagnostics industry, where he was president and chief executive officer from 2012 to 2017.
“Both Dr. Taub and Mr. Embro-Pantalony are widely-regarded forces in the biopharma industry, bringing expert prowess in clinical oncology, corporate partnership strategy and board governance,” BriaCell’s Director and Acting Chairman of the Board Jamieson Bondarenko said in the news release. “On behalf of BriaCell’s Board of Directors, management team, and shareholders, I would like to thank Dr. Babaei, Mr. Sharan and Mr. Schmieg for their significant contributions to BriaCell and wish them the very best in their future ventures.”
To view the full press release, visit http://nnw.fm/cwPE8
BriaCell is an immuno-oncology focused biotechnology company developing targeted and safe approaches for the management of cancer. BriaCell is currently conducting a Phase I/IIa clinical trial of Bria-IMT, its lead candidate, in a combination study with pembrolizumab [Keytruda; manufactured by Merck & Co., Inc.] or ipilimumab [Yervoy; manufactured by Bristol-Myers Squibb Company]. The combination study is listed in ClinicalTrials.gov as NCT03328026. BriaCell is developing Bria-OTS, an off-the-shelf personalized immunotherapy, for advanced breast cancer. Bria-OTS immunotherapy treatments are personalized to match the patient without the need for personalized manufacturing. Bria-OTS, which is expected to cover over 90 percent of the patient population, is designed to produce a potent and selective immune response against the cancer of each patient while eliminating the time, expense, and complex manufacturing logistics associated with other personalized immunotherapies. For more information, visit the company’s website at www.BriaCell.com
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive instant SMS alerts, text STOCKS to 77948
For more information please visit https://www.NetworkNewsWire.com